Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI). DOR exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with 50% in...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Antimicrob Agents Chemother
Main Authors: Feng, Meizhen, Sachs, Nancy A., Xu, Min, Grobler, Jay, Blair, Wade, Hazuda, Daria J., Miller, Michael D., Lai, Ming-Tain
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Microbiology 2016
Fag:
Antiviral Agents
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4808216/
https://ncbi.nlm.nih.gov/pubmed/26833152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02650-15
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker